GAITHERSBURG, Md., June 08, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M. Glenn, M.D., President of Research and Development, will join other vaccine industry leaders for a panel discussion at 2020 BIO Digital. Taking place on Tuesday, June 9 at 11:30 a.m. EDT, the panel will discuss COVID-19 vaccines. The conversation will consider the complex path from lab to clinical trials, the impact of the evolving science on candidate development and consider how collaboration will bring life-saving vaccines to the world.

Details for the panel are as follows:

Title: Leveraging Platforms and Partnerships to Develop COVID-19 Vaccines in Record Time
   
Date and Time: Tuesday, June 9, 11:30 a.m. PDT
   
Moderator: Mark McClellan, M.D., Director, Duke Margolis Center for Health Policy
   
Panelists: Dr. Glenn
Margaret Hamburg, M.D., Foreign Secretary, National Academy of Medicine
Peter Marks, M.D., Ph.D., Director, Center for Biologics Evaluation and Research, United States Food and Drug Administration
Paul Stoffels, M.D., Vice Chairman of the Executive Committee, Chief Scientific Officer, Johnson & Johnson

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax recently initiated development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July of 2020. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Contacts:

Investors
Novavax, Inc.
Erika Trahan
[email protected]
240-268-2022

Westwicke
John Woolford
[email protected]
443-213-0506

Media
Brandzone/KOGS Communication
Edna Kaplan
[email protected]
617-974-8659

Primary Logo